Zhao Xiang-Yu, Chang Ying-Jun, Huang Xiao-Jun
Peking University Institute of Hematology, Peking University People Hospital, Beijing 100044, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):746-9.
This study was purposed to investigate the killer immunoglobulin-like receptor (KIR) genotype in patients with hematological malignancies. The sequence specific primer-polymerase chain reaction (PCR-SSP) technique was performed for the amplification of six inhibitory KIR genes (KIR2DL1-2DL4, 3DL1-3DL2) and six activating KIR genes (KIR2DS1-S5, 3DS1). The methods of KIR-SSP was used to determine the KIR genotypes of 54 leukemia patients, including 14 patients with acute myeloid leukemia (AML), 16 with acute lymphoblastic leukemia (ALL), 20 with chronic myeloid leukemia (CML), 3 with myelodysplastic syndrome (MDS) and 1 with acute myeloid-lymphoblast leukemia (AMLL). 54 patients were classified as high risk group (n = 27) and standard risk group (n = 27). The expression of KIR in NK cells and T cells was detected by flow cytometry. The frequencies of activating KIR genes in standard risk group were higher than those in high risk group, especially 2DS1 (p = 0.014), or 2DS2 (p = 0.046), or 3DS1 (p = 0.027). However, the frequencies of inhibitory KIR genes in standard risk group were similar to those in high risk group (p > 0.05). The frequencies of activating KIR genes were also higher in standard risk patients with acute AML, as compared with those in high risk patients with acute AML, particularly 2DS1 (66.7% vs 29.4%, p = 0.022), 2DS2 (57.6% vs 17.6%, p = 0.013), and 2DS3 (33.3% vs 5.9%, p = 0.039). The percentages of patients in high-risk group who expressed more than two kinds of activating KIRs were lower that those in standard-risk group (p = 0.035). There was no difference in the expressions of CD158a, CD158b, and CD158e on NK cells and T cells between high-risk group and standard-risk group (p > 0.05). In conclusions, different expressions of activating KIR genes were found in patients between high-risk group and standard-risk group.
本研究旨在调查血液系统恶性肿瘤患者的杀伤细胞免疫球蛋白样受体（KIR）基因型。采用序列特异性引物聚合酶链反应（PCR-SSP）技术扩增6个抑制性KIR基因（KIR2DL1-2DL4、3DL1-3DL2）和6个激活性KIR基因（KIR2DS1-S5、3DS1）。运用KIR-SSP方法检测54例白血病患者的KIR基因型，其中包括14例急性髓系白血病（AML）患者、16例急性淋巴细胞白血病（ALL）患者、20例慢性髓系白血病（CML）患者、3例骨髓增生异常综合征（MDS）患者和1例急性髓系-淋巴细胞白血病（AMLL）患者。54例患者被分为高危组（n = 27）和标准风险组（n = 27）。通过流式细胞术检测NK细胞和T细胞中KIR的表达。标准风险组中激活性KIR基因的频率高于高危组，尤其是2DS1（p = 0.014）、2DS2（p = 0.046）或3DS1（p = 0.027）。然而，标准风险组中抑制性KIR基因的频率与高危组相似（p > 0.05）。与高危急性AML患者相比，标准风险急性AML患者中激活性KIR基因的频率也更高，尤其是2DS1（66.7%对29.4%，p = 0.022）、2DS2（57.6%对17.6%，p = 0.013）和2DS3（33.3%对5.9%，p = 0.039）。高危组中表达两种以上激活性KIR的患者百分比低于标准风险组（p = 0.035）。高危组和标准风险组之间NK细胞和T细胞上CD158a、CD158b和CD158e的表达无差异（p > 0.05）。总之，高危组和标准风险组患者中激活性KIR基因的表达存在差异。
